spacer
home > > autumn 2008 > future functions
PUBLICATIONS


Future Functions

It is nearly 20 years since the first commercial imaging core laboratory was founded. Today, there are numerous commercial imaging core laboratories, numerous international imaging biomarker meetings and regulatory guidance documents to support the use of imaging in drug development. Many academic, government and commercial entities have contributed to the growth of this approach, which has become a mainstream tool for the development of numerous therapeutic drugs.

Medical imaging endpoints are accepted in many clinical trials, and when included in the study design, the FDA requires the implementation of a central, independent image review process. The proliferation of medical imaging endpoints and the resulting management, analysis and submission of medical imaging data has fostered the healthy growth of the medical imaging core lab industry, both for commercial and academic labs. The increase in the number of labs and studies for which they provide services led to a somewhat varied set of documentation and implementation of various technology methods for what is a largely consistent undertaking. Pharmaceutical trial sponsors and the FDA initiated the desire for standardisation in these trials, and DIA has provided the leadership needed to obtain collaboration from all affected parties.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
James Conklin is the Senior Vice President for medical and scientific affairs at ICON Medical Imaging. James is a John Hopkins-trained research physician with undergraduate and graduate training in electrical/computer engineering and a Masters degree in Management. He has been a Professor of Radiology at several medical schools, published over 100 scientific papers and edited four books. One of the textbooks, Imaging Techniques in Biology and Medicine, published by Academic Press in 1987, provided the technical foundation for Bio-Imaging Technologies, Inc. He is board certified in both internal medicine and nuclear medicine.
spacer
James Conklin
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Hope for a new treatment for the autoimmune neuromuscular disease Myasthenia Gravis (MG)

- The biotech companies 3P Biopharmaceuticals and Toleranzia collaborate for that MG treatment - MG is an orphan disease which has a major unmet medical need and a large market potential - The drug candidate,TOL2, has already achieved several positive preclinical results
More info >>

White Papers

Planning the Execution of a Viral Clearance Study

Eurofins BioPharma Product Testing

Viral clearance studies are a necessary component of any regulatory submission for clinical trials or commercial product approval for all biopharmaceutical products. These studies are performed to evaluate the capability of the purification process to remove or inactivate viruses that could potentially contaminate the starting material. They are complex studies that require substantial financial and personnel resources, as well as specialized scientific expertise to perform. As such, viral clearance studies are often performed at a qualified contract testing laboratory rather than in-house. When multiple parties are involved in this process, clear communication and a comprehensive understanding of the approach and timeline is critical.
More info >>

 
Industry Events

World Vaccine Congress Washington

27-29 September 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement